Amogh is a Venture Science at Synapto Ventures, assessing of early-stage life science opportunities with a focus on oncology, diagnostics, and therapeutic platforms.
Amogh brings deep technical expertise in oncology through his research experience, where he specialized in tumor metabolism and therapeutic vulnerabilities in pediatric cancers. Using multi-omic approaches and pre-clinical in vivo models, he gained deep expertise in preclinical study design, biomarker analysis, and early-stage drug evaluation.
Amogh has led multiple grant applications, presented at regional and international symposia, and served as Vice President of the Physiology Graduate Student Society at NUS.
His research has been published in peer-reviewed journals, and his most recent manuscript—focused on PLA2-drivenlipid metabolism in tumor-initiating cell.
Amogh holds a PhD in Cancer Biology from the Yong Loo Lin School of Medicine, National University of Singapore, and a dual BTech-MTech in Biotechnology from KIIT University, India.
